Erik Atkisson - 26 Jan 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role
GC & Chief Compliance Officer
Signature
/s/ Erik Atkisson
Issuer symbol
N/A
Transactions as of
26 Jan 2023
Net transactions value
$0
Form type
4
Filing time
30 Jan 2023, 20:15:13 UTC
Previous filing
11 Mar 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EIGR Stock Option (Right to Buy) Award $0 +26,750 $0.000000 26,750 26 Jan 2023 Common Stock 26,750 $1.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 50% on the first anniversary of the January 26, 2023 grant date, and as to the remaining 50% on June 26, 2024, subject to the Reporting Person's continuous service as of each such date. The option vests in full upon a change in control of the Issuer.